Biotech entity
Every one of those 1 sits in a single category, pharma. Tumor Progression is most often covered alongside MIT, which appears in 1 of these 1 story. Tumor Progression appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Tumor Progression is most often covered alongside MIT, which appears in 1 of these 1 story. Tumor Progression appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Tumor Progression. Shared-story counts are live from our verified record — not editorial picks.
MIT scientists have developed advanced predictive models designed to characterize the complex trajectory of tumor progression. By leveraging computational biology, these tools aim to provide clinicians with a roadmap of how cancer evolves, potentially transforming personalized treatment strategies.
Tumor Progression is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
